Preoperative mobilization of bone marrow-derived cells followed by revascularization surgery: early and long-term outcome

Int J Artif Organs. 2012 Jan;35(1):67-76. doi: 10.5301/ijao.5000021.

Abstract

Introduction: Coronary artery disease (CAD), along with its main complications such as acute myocardial infarction (AMI) and congestive heart failure (CHF), remains a serious worldwide problem and affects many patients despite the improvement of medical treatment. The possibility of the replacement of the infarcted areas by the re-generation of the myocardial cells has been long discussed and the mobilization of the stem cells from bone marrow (BMCs) to the peripheral blood (PB) induced by cytokines, represents a potential pathway to activate the regenerative process.

Patients and methods: We describe BMC mobilization and direct/indirect revascularization in 15 patients operated on for coronary artery bypass grafting (CABG) and/or mitral valve surgery and/or ventricular remodeling combined to multiple trans-myocardial punctures (Sen technique) in ungraftable non-viable fibrotic areas.

Results: Peak values of circulating BMCs were recorded between day +4 and day +6. We had no in-hospital (0-30 days) mortality. All the patients were discharged from the ICU after a median period of 2 days while the in-hospital length of stay was 10.5+4.2 days (range 7-21) and all patients were discharged in good clinical condition. There were two sudden deaths over the mid-term, at postoperative day (POD) 32 and 45 respectively.

Conclusions: Our study suggests that the combination of BMC mobilization and CABG may be safely performed. However, considering the small series, final conclusions about the benefit of this procedure must await a larger prospective study comparing the role of cytokines alone, myocardial perforation, and the combination of both.

Publication types

  • Case Reports
  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Bone Marrow Cells / drug effects*
  • Combined Modality Therapy
  • Coronary Artery Bypass* / adverse effects
  • Coronary Artery Bypass* / mortality
  • Coronary Artery Disease / complications
  • Coronary Artery Disease / mortality
  • Coronary Artery Disease / pathology
  • Coronary Artery Disease / physiopathology
  • Coronary Artery Disease / surgery*
  • Drug Administration Schedule
  • Female
  • Fibrosis
  • Granulocyte Colony-Stimulating Factor / administration & dosage*
  • Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage*
  • Heart Failure / etiology
  • Heart Failure / mortality
  • Heart Failure / pathology
  • Heart Failure / physiopathology
  • Heart Failure / surgery*
  • Hematopoietic Stem Cell Mobilization* / adverse effects
  • Hematopoietic Stem Cell Mobilization* / mortality
  • Humans
  • Injections, Subcutaneous
  • Italy
  • Length of Stay
  • Lenograstim
  • Male
  • Middle Aged
  • Myocardial Infarction / etiology
  • Myocardial Infarction / mortality
  • Myocardial Infarction / pathology
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / surgery*
  • Myocardium / pathology*
  • Pilot Projects
  • Preoperative Care
  • Prospective Studies
  • Punctures
  • Recombinant Proteins / administration & dosage
  • Risk Assessment
  • Stem Cells / drug effects*
  • Survival Analysis
  • Time Factors
  • Treatment Outcome

Substances

  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Lenograstim
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • molgramostim